
-
Evolus NASDAQ:EOLS Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.
Location: 520 Newport Center Dr Ste 1200, California, 92660-7022, United States | Website: www.evolus.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
930.7M
Cash
85.04M
Avg Qtr Burn
-5.499M
Short % of Float
11.58%
Insider Ownership
10.42%
Institutional Own.
82.77%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Jeuveau (prabotulinumtoxinA-xvfs) Details Glabellar lines , Benign tumor | Approved Quarterly sales | |
Evolysse™ Details Nasolabial fold lines | Phase 3 Update | |
Jeuveau “Extra-Strength” Details Glabellar lines | Phase 2 Update |